The abnormal properties of cancer cells are due in part to the inappropriate activation of some transcription factors (TFs) and the inactivation of others. Understanding how TFs function should allow the design of therapies that modify the abnormal TFs that contribute to oncogenesis. Most regulatory TFs are modular proteins with distinct DNA binding and activation domains. The mechanisms by which DNA binding domains function are well understood, but little is known about how activation domains function. Activation domains stimulate pol Il initiation from a complicated preinitiation complex composed of general TFs and pol Il. We propose to study the activation domains of the strong viral activators adenovirus 2 E1A, Epstein-Barr Virus Zta, and herpes simplex virus VP16; as well as the important tumor suppressor p53. The studies depend on the ability to purify functional TFIID, the complex general transcription factor composed of the TATA-binding protein (TBP) and TAFs that initiates preinitiation complex assembly at promoters with a TATA-box. A minor nuclear protein, CR3BP, has been identified with the predicted properties of an E1A coactivator: it binds the wt E1A activation domain, but not to point mutants defective in activation that do bind TBP. If additional experimentation is consistent with E1A coactivator function, a cDNA encoding CR3BP will be cloned and used to analyze its transcriptional activity. Regions on the surface of TBP that interact with E1A and other activation domains, general TFs and TAFs will be analyzed by introducing amino acid substitutions into each of its 91 surface amino acid residues that do not contact DNA. TFIID containing mutant TBPs that bind general TFs and TAFs normally but are defective for activated transcription will be isolated and used in assays of activation domain binding and preinitiation complex assembly to determine which step in activated assembly, pol II initiation or promoter clearance is defective. Zta activates assembly of TFIID and TFIIA on promoter DNA, but this stimulation is not sufficient to account completely for Zta activation. Steps in preinitiation complex assembly subsequent to D-A assembly will be assayed using agarose gels capable of resolving DNA protein complexes of >10(6) Da and a gel filtration assay to detect factor binding to plasmid templates. Activation of pol II initiation and promoter clearance will also be analyzed. Similar studies will analyze activation by E1A and p53 and activation by combinations of activators on synthetic templates with binding sites for two types of activators. Specific antibodies raised against a recently cloned subunit of the pol III factor TFIIIC will be used to analyze the mechanism of TFIIIC regulation in response to viral infection and growth factors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA025235-19
Application #
2390630
Study Section
Experimental Virology Study Section (EVR)
Project Start
1979-04-01
Project End
2000-03-31
Budget Start
1997-04-01
Budget End
1998-03-31
Support Year
19
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Microbiology/Immun/Virology
Type
Schools of Arts and Sciences
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Hsu, Emily; Pennella, Mario A; Zemke, Nathan R et al. (2018) Adenovirus E1A Activation Domain Regulates H3 Acetylation Affecting Varied Steps in Transcription at Different Viral Promoters. J Virol 92:
Ferrari, Roberto; Gou, Dawei; Jawdekar, Gauri et al. (2014) Adenovirus small E1A employs the lysine acetylases p300/CBP and tumor suppressor Rb to repress select host genes and promote productive virus infection. Cell Host Microbe 16:663-76
Gallaher, Sean D; Berk, Arnold J (2013) A rapid Q-PCR titration protocol for adenovirus and helper-dependent adenovirus vectors that produces biologically relevant results. J Virol Methods 192:28-38
Ferrari, Roberto; Su, Trent; Li, Bing et al. (2012) Reorganization of the host epigenome by a viral oncogene. Genome Res 22:1212-21
Kawamata, N; Pennella, M A; Woo, J L et al. (2012) Dominant-negative mechanism of leukemogenic PAX5 fusions. Oncogene 31:966-77
Gil, J S; Gallaher, S D; Berk, A J (2010) Delivery of an EBV episome by a self-circularizing helper-dependent adenovirus: long-term transgene expression in immunocompetent mice. Gene Ther 17:1288-93
Ferrari, Roberto; Berk, Arnold J; Kurdistani, Siavash K (2009) Viral manipulation of the host epigenome for oncogenic transformation. Nat Rev Genet 10:290-4
Gallaher, Sean D; Gil, Jose S; Dorigo, Oliver et al. (2009) Robust in vivo transduction of a genetically stable Epstein-Barr virus episome to hepatocytes in mice by a hybrid viral vector. J Virol 83:3249-57
Balamotis, Michael A; Pennella, Mario A; Stevens, Jennitte L et al. (2009) Complexity in transcription control at the activation domain-mediator interface. Sci Signal 2:ra20
Wang, Wei; Huang, Lu; Huang, Yan et al. (2009) Mediator MED23 links insulin signaling to the adipogenesis transcription cascade. Dev Cell 16:764-71

Showing the most recent 10 out of 54 publications